{"entity":{"type":"insider","cik":"0001278271","url":"/insider/0001278271","json_url":"/insider/0001278271.json","name":"PYKETT MARK JEROME","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":8,"first":"2005-04-07","last":"2014-05-13","span_basis":"filed_date"},"name_variants":[{"name":"PYKETT MARK JEROME","source":"filing","n_filings":8,"first_seen":"2005-04-07","last_seen":"2014-05-13"}],"transactions":[{"id":7056835,"accession":"0001225208-14-012886","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001225208-14-012886","line_url":"/filing/0001225208-14-012886#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001278271","owner_name":"PYKETT MARK JEROME","owner_display_name":"PYKETT MARK JEROME","owner_url":"/insider/0001278271","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":1.34,"price_display":"1.34","price_state":"stated","total_value":13400.0,"total_display":"13,400.00","total_whole":"13,400","shares_owned_after":292674.0,"shares_owned_after_display":"292,674","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-05-09","filed_date":"2014-05-13","scope":"insider"},{"id":6750543,"accession":"0001225208-14-008078","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001225208-14-008078","line_url":"/filing/0001225208-14-008078#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001278271","owner_name":"PYKETT MARK JEROME","owner_display_name":"PYKETT MARK JEROME","owner_url":"/insider/0001278271","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":120000.0,"shares_display":"120,000","price_per_share":1.96,"price_display":"1.96","price_state":"stated","total_value":235200.0,"total_display":"235,200.00","total_whole":"235,200","shares_owned_after":282674.0,"shares_owned_after_display":"282,674","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-03-10","filed_date":"2014-03-11","scope":"insider"},{"id":5341864,"accession":"0001225208-13-023142","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001225208-13-023142","line_url":"/filing/0001225208-13-023142#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001278271","owner_name":"PYKETT MARK JEROME","owner_display_name":"PYKETT MARK JEROME","owner_url":"/insider/0001278271","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10900.0,"shares_display":"10,900","price_per_share":1.35,"price_display":"1.35","price_state":"stated","total_value":14715.0,"total_display":"14,715.00","total_whole":"14,715","shares_owned_after":402674.0,"shares_owned_after_display":"402,674","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-11-08","filed_date":"2013-11-08","scope":"insider"},{"id":5486117,"accession":"0001225208-13-007844","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001225208-13-007844","line_url":"/filing/0001225208-13-007844#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001278271","owner_name":"PYKETT MARK JEROME","owner_display_name":"PYKETT MARK JEROME","owner_url":"/insider/0001278271","role":"Director, Officer (Pres. & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres. & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1850.0,"shares_display":"1,850","price_per_share":2.7,"price_display":"2.70","price_state":"stated","total_value":4995.0,"total_display":"4,995.00","total_whole":"4,995","shares_owned_after":355914.0,"shares_owned_after_display":"355,914","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-15","filed_date":"2013-03-18","scope":"insider"},{"id":3233580,"accession":"0001225208-12-019611","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001225208-12-019611","line_url":"/filing/0001225208-12-019611#line-1","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","issuer_ticker":"NAVB","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001278271","owner_name":"PYKETT MARK JEROME","owner_display_name":"PYKETT MARK JEROME","owner_url":"/insider/0001278271","role":"Director, Officer (Pres. & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres. & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":2.638,"price_display":"2.64","price_state":"stated","total_value":10552.0,"total_display":"10,552.00","total_whole":"10,552","shares_owned_after":307300.0,"shares_owned_after_display":"307,300","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-11","filed_date":"2012-09-14","scope":"insider"},{"id":8930889,"accession":"0001225208-11-020385","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001225208-11-020385","line_url":"/filing/0001225208-11-020385","is_derivative":false,"issuer_cik":"0000810509","issuer_name":"NEOPROBE CORP","issuer_ticker":"NEOP","issuer_name_source":null,"issuer_url":"/issuer/0000810509","owner_cik":"0001278271","owner_name":"PYKETT MARK JEROME","owner_display_name":"PYKETT MARK JEROME","owner_url":"/insider/0001278271","role":"Director, Officer (Pres. & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Pres. & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4400.0,"shares_display":"4,400","price_per_share":2.5952272727272727,"price_display":"2.60","price_state":"stated","total_value":11419.0,"total_display":"11,419.00","total_whole":"11,419","shares_owned_after":2700.0,"shares_owned_after_display":"2,700","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-08-22","filed_date":"2011-08-23","scope":"insider","n_lines":4},{"id":1206572,"accession":"0001144204-05-010776","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-05-010776","line_url":"/filing/0001144204-05-010776","is_derivative":false,"issuer_cik":"0001160308","issuer_name":"ADVENTRX PHARMACEUTICALS INC","issuer_ticker":"ANX","issuer_name_source":null,"issuer_url":"/issuer/0001160308","owner_cik":"0001278271","owner_name":"PYKETT MARK JEROME","owner_display_name":"PYKETT MARK JEROME","owner_url":"/insider/0001278271","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":1.698,"price_display":"1.70","price_state":"stated","total_value":5094.0,"total_display":"5,094.00","total_whole":"5,094","shares_owned_after":3000.0,"shares_owned_after_display":"3,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-04-06","filed_date":"2005-04-07","scope":"insider","n_lines":2},{"id":3937429,"accession":"0001209191-08-024280","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-08-024280","line_url":"/filing/0001209191-08-024280#line-1","is_derivative":false,"issuer_cik":"0001160308","issuer_name":"ADVENTRX PHARMACEUTICALS INC","issuer_ticker":"ANX","issuer_name_source":null,"issuer_url":"/issuer/0001160308","owner_cik":"0001278271","owner_name":"PYKETT MARK JEROME","owner_display_name":"PYKETT MARK JEROME","owner_url":"/insider/0001278271","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":2.08,"price_display":"2.08","price_state":"stated","total_value":1040.0,"total_display":"1,040.00","total_whole":"1,040","shares_owned_after":8000.0,"shares_owned_after_display":"8,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2004-05-24","filed_date":"2008-04-15","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":12,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":11,"open_market":true},{"code":"S","label":"Open-market sale","n":1,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":12},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000810509","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","url":"/issuer/0000810509","role":"Director, Officer (CEO)","n_filings":6,"first_seen":"2011-08-23","last_seen":"2014-05-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001160308","name":"ADVENTRX PHARMACEUTICALS INC","url":"/issuer/0001160308","role":"Director","n_filings":2,"first_seen":"2005-04-07","last_seen":"2008-04-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001278271","retrieved_at":"2026-08-26T11:25:57+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}